NextCure (NASDAQ:NXTC) Stock Rating Reaffirmed by Needham & Company LLC

NextCure (NASDAQ:NXTC)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Friday, Benzinga reports. They presently have a $4.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 161.44% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of NextCure in a research note on Friday.

NextCure Stock Performance

Shares of NXTC traded up $0.04 on Friday, reaching $1.53. The stock had a trading volume of 108,827 shares, compared to its average volume of 147,942. The firm has a 50-day moving average of $1.72 and a 200 day moving average of $1.40. NextCure has a twelve month low of $0.98 and a twelve month high of $2.57.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, equities analysts anticipate that NextCure will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On NextCure

Institutional investors have recently modified their holdings of the company. Cable Car Capital LLC purchased a new stake in shares of NextCure in the fourth quarter valued at $702,000. Assenagon Asset Management S.A. purchased a new stake in NextCure during the first quarter valued at about $952,000. Acuitas Investments LLC increased its stake in NextCure by 30.0% during the fourth quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after acquiring an additional 85,982 shares during the last quarter. Finally, Marquette Asset Management LLC purchased a new stake in shares of NextCure during the 4th quarter worth about $66,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.